MARCAINE SOLUTION

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

BUPIVACAINE HYDROCHLORIDE

Доступна с:

PFIZER CANADA ULC

код АТС:

N01BB01

ИНН (Международная Имя):

BUPIVACAINE

дозировка:

125MG

Фармацевтическая форма:

SOLUTION

состав:

BUPIVACAINE HYDROCHLORIDE 125MG

Администрация маршрут:

BLOCK/INFILTRATION

Штук в упаковке:

50ML

Тип рецепта:

Ethical

Терапевтические области:

LOCAL ANESTHETICS

Обзор продуктов:

Active ingredient group (AIG) number: 0108896001; AHFS:

Статус Авторизация:

APPROVED

Дата Авторизация:

2004-05-04

Характеристики продукта

PRODUCT MONOGRAPH
MARCAINE
®
(Bupivacaine Hydrochloride Injection USP)
2.5 mg/mL, 5 mg/mL and 7.5 mg/mL
MARCAINE
® SPINAL
(Bupivacaine Hydrochloride in Dextrose Injection USP)
7.5 mg/mL
MARCAINE
® E
(Bupivacaine Hydrochloride and Epinephrine Injection USP)
Bupivacaine Hydrochloride 2.5 mg/mL and Epinephrine Bitartrate 9.1
mcg/mL
Bupivacaine Hydrochloride 5 mg/mL and Epinephrine Bitartrate 9.1
mcg/mL
Sterile Solution
Local Anesthetic
Pfizer Canada Inc.
17300 Trans-Canada Highway
Kirkland, Québec
H9J 2M5
Submission Control No.: 208287
Date of Revision:
September 6, 2017
_Product Monograph – Marcaine_
_®_
_, Marcaine_
_®_
_ Spinal, Marcaine_
_®_
_ E _
_Page 2 of 40_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................4
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................6
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................15
DOSAGE AND ADMINISTRATION
..............................................................................17
OVERDOSAGE
................................................................................................................23
ACTION AND CLINICAL PHARMACOLOGY
............................................................26
STORAGE AND STABILITY
..........................................................................................28
SPECIAL HANDLING INSTRUCTIONS
.......................................................................28
DOSAGE FORMS, COMPOSITION